Drugs / RTP-026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06465303 | Jul 2024 → Dec 2025 overdue | ST-elevation myocardial infarction | ResoTher Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | ResoTher Pharma | Results RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK resotherpharma.com ↗
today announced encouraging top-line results from a Phase 2a clinical study of its lead drug candidate, RTP-026, in patients with acute myocardial infarction. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | ResoTher Pharma | RTP-026, A POTENTIAL FIRST-IN-CLASS CARDIOPROTECTANT, SHOWS STRONG SAFETY AND PROMISING EFFICACY SIGNALS IN A PHASE 2a STUDY IN PATIENTS WITH SEVERE HEART ATTACK resotherpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTP-026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465303 ↗ |
| Route | Intravenous | “three 30-minute intravenous infusions of RTP-026 or placebo” NCT06465303 ↗ |